Diabetes, Metabolic and Endocrine Diseases

Prof. Drorit Neumann

Osteoporosis

Anemia is a serious global health concern estimated to affect a third of the world’s population. The introduction of erythropoietin (Epo) into clinical practice has revolutionized the treatment of this condition, although there is the risk of inadvertent effects that may be hazardous. Prof. Neumann has demonstrated that Epo is associated with a dual action of bone loss and immunomodulatory effects. Osteoporosis is the most common bone disease, affecting nearly half the population over https://droritneumannlab.com/ the age of 50. Neumann’s team studies Epo in mouse models and patients, in collaboration with bone experts and clinicians. Epo is a new player in osteoimmunology, and will link the effects of the hormone to a wide range of outcomes on bone and immune cells, and suggest methods to realize the therapeutic potential of Epo, maintaining immune competence as well as the erythroid stimulating-effect while attenuating the risk for bone loss.

Prof. Neumann, PhD, Department of Cell and Developmental Biology, completed her PhD at the Weizmann Institute and was trained as a postdoctoral fellow with Prof. Lodish at MIT. She set up and coordinated the EpoCan FP7 Consortium, which assessed the long-term risks of Epo and investigated better Epoetin-driven treatment modalities. She currently serves as Dean of Students at Tel Aviv University and holds the Lily and Avraham Gildor Chair for the Investigation of Growth Factors. She is the Dean of Students at Tel Aviv University.